Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
USA Basketball finalizing Paris Olympics roster, AP sources say'I was afraid for my life' — Orlando Bloom puts himself in peril for new TV seriesBond denied for 4 'God's Misfits' defendants in the killing of 2 Kansas womenHouse panel says China subsidizes fentanyl production to fuel crisis in the United StatesHow you CAN go on safari on a budget: From gorillas in Uganda to South African elephantsHow much of England's motorway network has no hard shoulder? This map reveals all...How ancient hatreds are reshaping the Middle East and forging unlikely alliances. The rise of IranMinnesota toddler dies after fall from South Dakota hotel windowAlaska Airlines has brief ground stop due to technical issueRookie Keaton Winn throws six solid innings. Giants beat Marlins 3
3.3224s , 6502.8671875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Capsule news portal